A Phase 4 interventional study of ω-3 fish oil lipid emulsion and Conventional lipid without ω-3 fish oil in Parenteral Nutrition, Nutritional Status and Major Abdominal Surgery, sponsored by Second Affiliated Hospital of Nanchang University. Not yet recruiting at 7 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Second Affiliated Hospital of Nanchang University · Phase 4, Interventional, and Treatment
The goal of this study is to explore if preoperative ω-3 fish oil lipid emulsion parenteral nutrition (PN) can improve postoperative outcomes in patients undergoing major abdominal surgery. The main questions it aims to answer are:
Participants will:
99 studies on the registry are indexed under Hyperphagia; 26 are open to participants now.
This study's planned enrollment of 158 is above the median of 50 across 85 interventional studies indexed under Hyperphagia.
Browse Hyperphagia studies →Second Affiliated Hospital of Nanchang University is the lead sponsor of 81 studies on the registry; 49 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Two days before the scheduled surgery, while maintaining a normal diet, an intravenous infusion of parenteral nutrition solution prepared from ω-3 fish oil and medium/long chain fat emulsion was administered daily.
Drug: ω-3 fish oil lipid emulsion
Receiving parenteral nutrition without fish oil fat emulsion with equal nitrogen and heat content
Drug: Conventional lipid without ω-3 fish oil
In the ω-3 group, receive preoperative parenteral nutrition containing ω-3 fish oil lipid emulsion.
Receiving parenteral nutrition without fish oil fat emulsion with equal nitrogen and heat content
Serum albumin and prealbumin levels
Levels of serum albumin and prealbumin will be measured at baseline (preoperative Day 1) and postoperatively on Days 1, 3, and 7. If discharged before Day 7, the final measurement will be taken on the day of discharge.
Time frame: Preoperative Day 1, and postoperative Days 1, 3, and 7
Length of hospital stay (days)
Length of hospital stay will be calculated as the number of days from surgery to discharge. If a patient is still hospitalized at the end of the study period, the outcome will be censored at 30 days.
Time frame: From surgery to hospital discharge (up to 30 days)
White blood cell count, lymphocyte count, and C-reactive protein (CRP) levels
Levels of white blood cells (WBC), lymphocytes, and C-reactive protein (CRP) will be measured from blood samples at baseline (preoperative Day 1) and postoperatively on Days 1, 3, and 7.
Time frame: Baseline (Day -1), and postoperative Days 1, 3, and 7
Incidence of postoperative complications (hypoproteinemia, anastomotic leakage, ileus, postoperative hemorrhage, renal failure, and thromboembolic events)
Postoperative complications will be monitored and recorded from the end of surgery until hospital discharge, with a maximum follow-up of 30 days after surgery. The complications assessed include hypoproteinemia, anastomotic leakage, ileus, postoperative hemorrhage, renal failure, and thromboembolic events.
Time frame: From surgery to hospital discharge (up to 30 days post-surgery)
Total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels
Serum levels of total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) will be measured from blood samples at baseline (preoperative Day 1) and postoperatively on Days 1, 3, and 7.
Time frame: Baseline (Day -1), and postoperative Days 1, 3, and 7
Time to first flatus and defecation
Time to first flatus and time to first defecation will be defined as the interval (in hours or days) from the end of surgery to the first postoperative passage of flatus or defecation, respectively. Patients will be followed daily during hospitalization.
Time frame: From the end of surgery up to postoperative Day 7
Plan to share: Yes — After the article is published, de-identified data can be obtained from corresponding author upon reasonable request.
Supporting information: Study protocol, Clinical study report
Time frame: After the article is published
Access criteria: After the article is published, all can access the IPD and supporting information from corresponding author upon reasonable request.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jan 2027, 3 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital of Nanchang University